• Explore /
  • Poster
  • / GO39775: A multicenter phase I trial evaluating the safety, pharmacokinetics, and activity of BFCR4350A, a FcRH5/CD3 T-cell dependent bispecific antibody, in patients with relapsed or refractory multiple myeloma.

GO39775: A multicenter phase I trial evaluating the safety, pharmacokinetics, and activity of BFCR4350A, a FcRH5/CD3 T-cell dependent bispecific antibody, in patients with relapsed or refractory multiple myeloma.

Abstract Video & Slides Poster

Authors

null

Adam D. Cohen

Abramson Cancer Center and University of Pennsylvania, Philadelphia, PA

Adam D. Cohen , Suzanne Trudel , Peter A. Forsberg , Rafael Fonseca , Amrita Y. Krishnan , Andrew Spencer , Jesus G. Berdeja , Sarah M. Hamirani , Mengsong Li , James Cooper , Simon J. Harrison

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Hematologic Malignancies—Plasma Cell Dyscrasia

Track

Hematologic Malignancies

Sub Track

Multiple Myeloma

Clinical Trial Registration Number

NCT03275103

Citation

J Clin Oncol 38: 2020 (suppl; abstr TPS8551)

DOI

10.1200/JCO.2020.38.15_suppl.TPS8551

Abstract #

TPS8551

Poster Bd #

451

Abstract Disclosures

Similar Posters

First Author: Ravi Vij

First Author: Sosana Delimpasi

First Author: Krish Patel

First Author: Kelly C. Goldsmith